# A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.

> **NCT01745965** · PHASE2 · COMPLETED · sponsor: **West German Study Group** · enrollment: 380 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** T-DM1
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01745965
- **Lead sponsor:** West German Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-02
- **Final completion:** 2025-01-15
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2025-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01745965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01745965, "A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01745965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*